Personalised testing helps breast cancer patients avoid chemotherapy

Prognostic tests analyzing tumour biology allow oncologists to tailor treatment plans and potentially spare patients from the side effects of chemotherapy.

Personalised testing helps breast cancer patients avoid chemotherapy
Photo: Deccan Chronicle

Oncologists are increasingly moving away from one-size-fits-all treatment plans toward personalised approaches based on the specific biology of a tumour. This shift allows doctors to determine which treatments will benefit an individual patient rather than relying solely on tumour size, grade, or stage.

Prognostic tests are playing a role in this transition by providing information about the likelihood of cancer returning. For example, the CanAssist Breast test by OncoStem Diagnostics analyses protein biomarkers in a tumour alongside clinical information to assess recurrence risk.

Riya, a 31-year-old woman whose name was changed, used a recurrence risk prediction test to help decide her treatment for early-stage breast cancer. Because her test results showed a low risk of recurrence, chemotherapy was left out of her treatment plan. She underwent surgery and radiation, had a child the following year, and later completed five years of hormone therapy.

Dr. Rakesh Reddy Boya, a senior consultant medical and hemato-oncologist, said treatment decisions are now guided by the genetic changes present in a particular tumour. Dr. Manjiri Bakre, CEO and founder of OncoStem Diagnostics, explained that these tests help doctors assess how much benefit a patient might get from chemotherapy.

The ability to avoid chemotherapy can provide relief from physical and financial burdens, though it can also raise concerns about increasing the risk of recurrence. Dr. Praveen Dadireddy, a surgical oncologist, said that presenting data and evidence helps patients accept effective plans that avoid chemotherapy while still offering a complete cure.

Key facts

  • Personalised cancer treatment uses tumour biology and genetic changes to tailor treatment plans to individual patients.
  • Prognostic tests like CanAssist Breast analyse protein biomarkers to predict the risk of breast cancer recurrence.
  • Low recurrence risk scores can allow patients to safely avoid chemotherapy in some early-stage breast cancer cases.

Three perspectives

Neutral

Oncologists use prognostic tests to understand tumour biology and determine if chemotherapy is necessary for an individual patient.

Positive

Personalised treatment plans can allow patients to avoid the side effects and financial burdens of chemotherapy while still offering a complete cure.

Negative

Opting out of chemotherapy can raise concerns for patients regarding whether it might increase the risk of the cancer returning.

Your week in news, every Wednesday

The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.

Choose your news coverage

Please choose and confirm your coverage.

Study identifies racial differences in pancreatic cancer tumor cells
Next storyStudy identifies racial differences in pancreatic cancer tumor cells

All sections

Edition